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Introduction
Destruction of articular cartilage is an irreversible conse-
quence of arthritis. Cartilage consists of two major compo-
nents, a type-II-collagen-fibril network with associated
small proteoglycans, and proteoglycan aggregates com-
posed of a noncovalent association between aggrecan,
hyaluronate, and link protein. In arthritis, proteoglycan
degradation is thought to be an early and reversible
process, whereas the breakdown of the collagen network
is believed to be irreversible, contributing to loss of joint
function. While free radical attack and the action of gly-
cosidases may play a role in cartilage deterioration, the
most important degradative agents are proteolytic
enzymes.
Proteases
Proteolytic cleavage of the major components of the carti-
lage extracellular matrix is effected by a number of pro-
teases, many of which are synthesized by chondrocytes
and synovial cells in response to inflammatory stimuli.
Members of each of the four classes of protease –
serine/threonine proteases, cysteine proteases, aspartic
proteases, and metalloproteases – have been implicated
in the degradation of cartilage. However, current data indi-
cate that the initial steps in matrix breakdown are extracel-
lular processes involving metalloproteases. This class of
enzyme is characterized by the presence, within the active
site, of a metal ion (usually zinc), which is required for cat-
alytic activity. Of the metalloproteases, the members of
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While many proteases in articular cartilage have been described, current studies indicate that
members of two families of metalloproteases – MMPs and the ADAMTSs – are responsible for the
degradation of the major components of this tissue. Collagenases (MMPs) make the first cleavage in
triple-helical collagen, allowing its further degradation by other proteases. Aggrecanases (ADAMTSs),
in conjunction with other MMPs, degrade aggrecan, a component of the proteoglycan aggregate. Anti-
neoepitope antibodies that recognize the cleavage products of collagen and aggrecan generated by
these enzymes are now available and are being used to detect the sites of action and to quantitate
degradation products.
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two families, the matrix metalloproteases (MMPs) and the
ADAMTSs (a disintegrin and a metalloprotease with
thrombospondin motifs) family, have been implicated in
the breakdown of collagen and aggrecan, respectively.
These enzymes are members of the M10 and M12 pepti-
dase families as classified in the universal protease data-
base, MEROPS [1].
Cleavage of peptide bonds is a very simple chemical
reaction and many proteolytic enzymes are relatively small
proteins (~30 kDa) consisting simply of a binding site to
accommodate about six amino acid residues of the sub-
strate and the catalytic machinery. Other proteases, in
particular the metalloproteases involved in matrix degra-
dation, have a more sophisticated, multidomain composi-
tion, in which additional protein elements are present,
giving additional functions to the protease. These include
assisting in substrate binding by attachment at sites
remote from where peptide bond cleavage occurs, and
binding to nonsubstrate molecules in the extracellular
matrix, allowing appropriate localization of the enzyme.
The MMPs
The MMPs form a multigene family and can be classified
into subfamilies on the basis of domain structure and sub-
strate selectivity. A convenient grouping is that of collage-
nases, stromelysins, gelatinases, and membrane-type
MMPs (MT-MMPs) (Fig. 1). Of these enzymes, the colla-
genases (MMP-1, -8, and -13) are the most specific, since
they alone are able to degrade native fibrillar collagens.
Cleavage occurs at a single locus, to yield fragments
three-quarters and one-quarter the size of the original mol-
ecule. Domain substitution experiments have shown that
the hemopexin region of collagenase is required for the
catalytic domain to cleave triple-helical collagen, but the
exact mechanism underlying this interaction is still not
clear [2]. The three mammalian collagenases exhibit differ-
ing substrate specificities, with MMP-13 preferentially
cleaving the major collagen constituent of cartilage, type II
collagen [3]. Once the initial cleavage has been made in
the collagen fibrils, the triple helix unwinds, rendering the
resulting fragments excellent substrates for the gelatinases,
MMPs -2 and -9. However, cleavage of the collagen fibril
Figure 1
Schematic representation of the domain structure of the matrix metalloproteinases (MMPs) associated with cartilage degradation. The sequence
HEXXH is a conserved motif in this family of metalloproteases. The two histidine residues (H) are ligands for the essential zinc ion, and the side
chain of the glutamic acid (E) acts as a general base for peptide bond cleavage. MMP-1, -8, and -13, collagenases; MMP-3, stromelysin; MMP-2
and -9, gelatinases; MMP-7, matrilysin; MMP-14, membrane type metalloproteinase-1
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itself may require clearance of small proteoglycans and
cleavage of interfibrillar cross-links in order for the collage-
nases to access triple-helical regions. The additional ele-
ments in the gelatinases (the fibronectin-type-II repeats
and the hemopexin domain) assist proteolysis by binding
to the substrate and also enable the enzyme to attach to
other components of the connective tissue matrix [4]. The
stromelysins are characterized by a broad substrate speci-
ficity and broad optimum pH range and are able to
degrade many of the extracellular matrix proteins [5],
including gelatins, proteoglycans, fibronectin, and type IX
collagen. The MT-MMPs are a more recently identified
subgroup of the MMPs, which contain a transmembrane
C-terminal domain. It has been shown [6] that MT1-MMP
is capable of digesting fibrillar type collagens I, II, and III
into the characteristic three-quarter and one-quarter frag-
ments, preferentially cleaving type I collagen, as well as
degrading other extracellular components, including
gelatin, proteoglycan, fibronectin, and laminin.
Control of MMP synthesis, activation, and activity is tightly
regulated under physiological conditions. Thus, all the
MMPs are synthesized as inactive proenzymes. Enzyme
latency is maintained by ligation of a cysteine residue in
the prodomain to the active-site Zn2+  ion. Activation
occurs via complex, highly regulated intermolecular prote-
olytic cascades leading to destabilization of the Cys–Zn
interaction [7], followed by a second cleavage that results
in the release of the prodomain from the active enzyme.
While many pathways for MMP activation have been
demonstrated using in vitro model systems, in most cases
the actual in vivo mechanisms are still not clear. MMP
activity is modulated by the naturally occurring endoge-
nous inhibitors of the MMPs, the tissue inhibitors of MMPs
(TIMPs). These molecules bind tightly to the active site of
activated MMPs with a 1:1 stoichiometry and have Ki
values of less than 10–9 M [8].
The MT-MMPs represent an important control point in
MMP activation. In contrast to most of the other MMPs,
the MT-MMPs are activated intracellularly, in the Golgi
apparatus, by the action of the serine protease furin, which
cleaves pro-MT-MMPs at a specific site. Once at the cell
surface, active MT1-MMP forms a trimolecular complex
with pro-MMP-2 and the inhibitor TIMP-2, resulting in the
activation of MMP-2.
It is apparent, then, that the accelerated turnover of colla-
gen associated with joint diseases may result from a
number of factors, including increased synthesis and acti-
vation of MMPs and/or an imbalance in levels of MMPs
and their inhibitors, the TIMPs.
The ADAMTS family
Of particular importance in cartilage turnover are members
of a very recently characterized family of metalloproteases
termed ADAMTSs [9]. These enzymes are similar in struc-
ture to the better-known ADAM (‘a disintegrin and a
metalloprotease’) family of membrane-bound metallo-
proteases [10], which in addition to the zinc-dependent
protease unit contain a disintegrin domain. In some
enzymes, this domain interacts with cell-surface integrins
to disrupt cell/matrix interactions but more generally can
be expected to mediate interactions with other cell and
matrix components. Instead of a membrane-spanning
domain, the ADAMTS members contain one or more
thrombospondin-type-I domains (Fig. 2). While two
members of this family (ADAMTS-2 and ADAMTS-3) are
collagen N-propeptide-processing enzymes, several other
ADAMTSs have been implicated in aggrecan degradation
in arthritis. It had been known for many years that in carti-
lage, aggrecan is cleaved at five unique sites along the
core protein after glutamic acid residues [11]. The activi-
ties mediating these cleavages were termed ‘aggre-
canases’, and using a direct approach, Elizabeth Arner’s
group purified two proteases [12,13] that fulfil this role
(aggrecanase-1 and -2), showing that they are members
of the ADAMTS family (ADAMTS-4 and -5). Subsequently,
it was demonstrated that ADAMTS-1, which had previ-
ously been characterized as an inflammation-associated
protein [14] but which is also expressed in cartilage [15],
is an aggrecanase [16]. The type-I-thrombospondin motifs
in these proteases bind to the sulfated GAGs in the
matrix, thus targeting the enzymes to the site of aggrecan
Available online http://arthritis-research.com/content/3/6/337
Figure 2
Schematic representation of the domain structure of ADAMTS members involved in aggrecan degradation. The conserved HEXXH motif is as in
Figure 1. ADAMTS-4 and -5, aggrecanase-1 and -2; ADAMTS-1, also termed METH-1 (metalloprotease and thrombospondin domains).
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Disintegrin-like domain Thrombospondin motifbreakdown [17] and increasing their degradative effi-
ciency. This property may also account for the reported
association of these activities with the chondrocyte mem-
brane [18]. Although regulation of the synthesis of
ADAMTS proteases is not fully understood, upregulation
of aggrecanase activity by interleukin 1 is well known. As
with the MT-MMPs, the proforms of aggrecanases contain
furin-processing motifs and exit from the Golgi apparatus
as active proteases. Recent in vitro studies indicate that
TIMP-3, but not TIMP-1, -2, or -4 [19,20], is a potent
inhibitor of ADAMTS-4 and -5 and thus is a potential
endogenous inhibitor of this class of enzyme.
Cysteine and other proteases
Members of the cysteine and aspartic protease classes
may also contribute to cartilage matrix degradation. Thus
the lysosomal enzymes, including cathepsins B, D, and L,
are thought to play a secondary role in cartilage degrada-
tion, involving intracellular digestion of products released
by other proteases. It has also been postulated that at
least some of these enzymes may function extracellularly
within the cartilage, with cathepsin B, for example, poten-
tially contributing to aggrecan breakdown [21]. The
protein is expressed in situ in synovial cells attached to
cartilage and bone at sites of erosion, and an enhanced
transcription of the protein was observed in these synovial
cells obtained from patients with rheumatoid arthritis com-
pared with the transcription in normal fibroblasts [22]. The
relative importance of different cysteine proteases in
osteoarthritis has been investigated recently, and again
cathepsin B appears to be a major factor [23]. In addition,
cathepsin K, which is the principal cysteine protease of
the osteoclast, has also been found in the synovium and
may contribute to cartilage degradation [24].
Evidence for the action of specific proteases
in cartilage
An important characteristic of the metalloproteases, which
is thought to mediate the initial steps in the cleavage of
collagen and aggrecan, is their specificity. Collagenases
make an initial cleavage at a specific weak point in the col-
lagen fibril, and aggrecanases cleave the core protein at
five well characterized sites. In addition, other MMPs, such
as stromelysin (MMP-3), cleave aggrecan at a well-charac-
terized site in the aggrecan core protein [25]. These cleav-
age events generate terminal neoepitopes that are
antigenically distinct from the same sequence in the intact
protein [26]. Antibodies produced against such neoepi-
topes have been used to demonstrate the sites of collage-
nase and aggrecanase action as well as those of other
metalloproteases such as stromelysin in normal and
pathological turnover of cartilage [27,28]. In addition,
since even after further processing the neoepitopes
survive on smaller peptides, they can be detected in body
fluids and used to evaluate the levels of ongoing matrix
degradation [29].
Conclusions: protease inhibition as a
therapeutic option
Evidence for the action of MMPs, aggrecanases, and
other proteases in the degradation of cartilage associated
with arthritis immediately suggests that their inhibition
would be a fruitful therapeutic approach. While to date
very few bioavailable cysteine protease inhibitors have
been developed, a massive effort to produce MMP
inhibitors over the past decade has resulted in several
potent compounds. As yet, their use in arthritis therapy
has been unsuccessful, in part because of an incomplete
understanding of the entire metalloprotease repertoire.
One of the problems in assessing the efficacy of protease
inhibitor therapy is the difficulty in measuring biological
outcome, since changes in cartilage metabolism are not
readily apparent, particularly to the patient. The availability
of methods to measure specific cartilage matrix fragments
in synovial fluid, blood, or urine that are indicative of
unique protease action, using specific anti-neoepitope
antibodies for aggrecan and collagen fragments, promises
to allow direct monitoring of the effect of different thera-
peutic approaches.
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